Please input keywords
Clinical Drug Development

The clinical development team of Eucure Biopharma is an outstanding team with global experience in clinical development, covering clinical medicine, science, clinical operations, registration affairs, data management, biostatistics, clinical supply chain, pharmacy, pharmacology and toxicology, clinical safety and pharmacovigilance. According to the strategic planning of Eucure Biopharma, we are based in Beijing, Shanghai and the United States. It is responsible for global clinical trials in China, the United States and Australia.

The clinical development team of Eucure Biopharma is highly experienced, with a full range of global and domestic drug development experience, and has a good network of relationships of clinical trial operations in China, the United States and Australia. In addition, our team has the ability to integrate various clinical development functions. Our core competencies lie in project strategy, registration affairs (FDA and NMPA), design of clinical study protocol, efficient and strong execution of clinical operations, and collaboration with KOL/PI.

In addition, the company has built a comprehensive R&D governance system that covers development supervision, standard operating procedures (SOP), and systematic supplier evaluation and management process, all of which are designed to safeguard patient safety.

Eucure Biopharma is a wholly-owned subsidiary of Biocytogen Group focusing on clinical development. Since the establishment of the clinical development team of Eucure Biopharma in October 2019, it has built a strong R&D pipeline targeting more than ten independently developed targets by Biocytogen. At present, two R&D products have obtained clinical approval from the United States and China respectively, three R&D products have entered Phase I clinical trials in Australia, two R&D products are about to enter Phase I clinical trials in China, and one R&D product has been jointly developed, which is the best proof of clinical development strength of Eucure Biopharma.